Last 12 months
Inside the activity.
0 purchase rows · 40 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 4 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 15 |
| Jul 2026 | 0 | 6 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 3 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 13, 2026 Filed Feb 17, 2026 22:48 UTC |
Gano KyleDirector · Chief Executive Officer
|
Tax withholdingCommon Stock | 5,378 | $124.12 | $667,517.36 |
DisclosureSEC source: 0001567160-26-000007 · wk-form4_1771368497.xml · nonDerivative · entry 8 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,815 F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:48 UTC |
Gano KyleDirector · Chief Executive Officer
|
GrantCommon Stock | 9,968 | $0.00 | $0.00 |
DisclosureSEC source: 0001567160-26-000007 · wk-form4_1771368497.xml · nonDerivative · entry 7 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,193 F2 · shares: On May 19, 2023, the Reporting Person was granted PRSUs representing the right to receive shares of the Issuer's common stock based upon the achievement of specified performance metrics over the three-year performance period ending on December 31, 2025. Effective February 13, 2026, the achievement of the applicable performance metrics and the resulting payout level were certified, and, as a result of such certification, the PRSUs vested at 125% of the target number of shares subject to the award. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:48 UTC |
Gano KyleDirector · Chief Executive Officer
|
Tax withholdingCommon Stock | 1,385 | $124.12 | $171,906.20 |
DisclosureSEC source: 0001567160-26-000007 · wk-form4_1771368497.xml · nonDerivative · entry 6 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,225 F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:48 UTC |
Gano KyleDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 2,566 | $0.00 | $0.00 |
DisclosureSEC source: 0001567160-26-000007 · wk-form4_1771368497.xml · nonDerivative · entry 5 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,610 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:48 UTC |
Gano KyleDirector · Chief Executive Officer
|
Tax withholdingCommon Stock | 1,210 | $124.12 | $150,185.20 |
DisclosureSEC source: 0001567160-26-000007 · wk-form4_1771368497.xml · nonDerivative · entry 4 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,044 F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:48 UTC |
Gano KyleDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 2,241 | $0.00 | $0.00 |
DisclosureSEC source: 0001567160-26-000007 · wk-form4_1771368497.xml · nonDerivative · entry 3 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,254 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:47 UTC |
Onyia JudeChief Scientific Officer
|
GrantRestricted Stock Unit · Derivative | 9,669 | $0.00 | $0.00 |
DisclosureSEC source: 0001894425-26-000005 · wk-form4_1771368439.xml · derivative · entry 13 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,669 Underlying: Common Stock · 9,669 shares Expires not disclosed F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F8 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030. F8 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:47 UTC |
Onyia JudeChief Scientific Officer
|
GrantStock Option · Derivative | 55,119 | $0.00 Strike: $124.12 | $0.00 |
DisclosureSEC source: 0001894425-26-000005 · wk-form4_1771368439.xml · derivative · entry 12 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,119 Underlying: Common Stock · 55,119 shares Expires 2036-02-13 F7 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2026 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:47 UTC |
Onyia JudeChief Scientific Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,717 | $0.00 | $0.00 |
DisclosureSEC source: 0001894425-26-000005 · wk-form4_1771368439.xml · derivative · entry 11 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,717 Underlying: Common Stock · 2,717 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 2,717 shares on February 13, 2024, vested as to 2,717 shares on February 13, 2025, vested as to 2,717 shares on February 13, 2026, and will vest as to 2,717 shares on February 13, 2027, subject to the terms and conditions of the award. F6 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 2,717 shares on February 13, 2024, vested as to 2,717 shares on February 13, 2025, vested as to 2,717 shares on February 13, 2026, and will vest as to 2,717 shares on February 13, 2027, subject to the terms and conditions of the award. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:47 UTC |
Onyia JudeChief Scientific Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,690 | $0.00 | $0.00 |
DisclosureSEC source: 0001894425-26-000005 · wk-form4_1771368439.xml · derivative · entry 10 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,380 Underlying: Common Stock · 2,690 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 2,690 shares on February 13, 2025, vested as to 2,690 shares on February 13, 2026, and will vest as to 2,690 shares on February 13, 2027, and 2,690 shares on February 13, 2028, subject to the terms and conditions of the award. F5 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 2,690 shares on February 13, 2025, vested as to 2,690 shares on February 13, 2026, and will vest as to 2,690 shares on February 13, 2027, and 2,690 shares on February 13, 2028, subject to the terms and conditions of the award. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:47 UTC |
Onyia JudeChief Scientific Officer
|
Tax withholdingCommon Stock | 10,755 | $124.12 | $1,334,910.60 |
DisclosureSEC source: 0001894425-26-000005 · wk-form4_1771368439.xml · nonDerivative · entry 8 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,780 F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:47 UTC |
Onyia JudeChief Scientific Officer
|
GrantCommon Stock | 19,935 | $0.00 | $0.00 |
DisclosureSEC source: 0001894425-26-000005 · wk-form4_1771368439.xml · nonDerivative · entry 7 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,535 F2 · shares: On May 19, 2023, the Reporting Person was granted PRSUs representing the right to receive shares of the Issuer's common stock based upon the achievement of specified performance metrics over the three-year performance period ending on December 31, 2025. Effective February 13, 2026, the achievement of the applicable performance metrics and the resulting payout level were certified, and, as a result of such certification, the PRSUs vested at 125% of the target number of shares subject to the award. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:47 UTC |
Onyia JudeChief Scientific Officer
|
Tax withholdingCommon Stock | 1,466 | $124.12 | $181,959.92 |
DisclosureSEC source: 0001894425-26-000005 · wk-form4_1771368439.xml · nonDerivative · entry 6 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,600 F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:47 UTC |
Onyia JudeChief Scientific Officer
|
Exercise / conversionCommon Stock | 2,717 | $0.00 | $0.00 |
DisclosureSEC source: 0001894425-26-000005 · wk-form4_1771368439.xml · nonDerivative · entry 5 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,066 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:47 UTC |
Onyia JudeChief Scientific Officer
|
Tax withholdingCommon Stock | 1,452 | $124.12 | $180,222.24 |
DisclosureSEC source: 0001894425-26-000005 · wk-form4_1771368439.xml · nonDerivative · entry 4 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,349 F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:47 UTC |
Onyia JudeChief Scientific Officer
|
Exercise / conversionCommon Stock | 2,690 | $0.00 | $0.00 |
DisclosureSEC source: 0001894425-26-000005 · wk-form4_1771368439.xml · nonDerivative · entry 3 Onyia Jude · CIK 0001894425 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,801 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:46 UTC |
Cooke JulieChief Human Resources Officer
|
GrantRestricted Stock Unit · Derivative | 4,754 | $0.00 | $0.00 |
DisclosureSEC source: 0001776977-26-000007 · wk-form4_1771368375.xml · derivative · entry 13 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,754 Underlying: Common Stock · 4,754 shares Expires not disclosed F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F9 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030. F9 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:46 UTC |
Cooke JulieChief Human Resources Officer
|
GrantStock Option · Derivative | 27,100 | $0.00 Strike: $124.12 | $0.00 |
DisclosureSEC source: 0001776977-26-000007 · wk-form4_1771368375.xml · derivative · entry 12 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,100 Underlying: Common Stock · 27,100 shares Expires 2036-02-13 F8 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2026 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:46 UTC |
Cooke JulieChief Human Resources Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,510 | $0.00 | $0.00 |
DisclosureSEC source: 0001776977-26-000007 · wk-form4_1771368375.xml · derivative · entry 11 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,510 Underlying: Common Stock · 1,510 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F7 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 1,509 shares on February 13, 2024, vested as to 1,509 shares on February 13, 2025, vested as to 1,510 shares on February 13, 2026, and will vest as to 1,510 shares on February 13, 2027, subject to the terms and conditions of the award. F7 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 1,509 shares on February 13, 2024, vested as to 1,509 shares on February 13, 2025, vested as to 1,510 shares on February 13, 2026, and will vest as to 1,510 shares on February 13, 2027, subject to the terms and conditions of the award. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:46 UTC |
Cooke JulieChief Human Resources Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,401 | $0.00 | $0.00 |
DisclosureSEC source: 0001776977-26-000007 · wk-form4_1771368375.xml · derivative · entry 10 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,802 Underlying: Common Stock · 1,401 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 1,401 shares on February 13, 2025, vested as to 1,401 shares on February 13, 2026, and will vest as to 1,401 shares on February 13, 2027, and 1,401 shares on February 13, 2028, subject to the terms and conditions of the award. F6 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 1,401 shares on February 13, 2025, vested as to 1,401 shares on February 13, 2026, and will vest as to 1,401 shares on February 13, 2027, and 1,401 shares on February 13, 2028, subject to the terms and conditions of the award. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:46 UTC |
Cooke JulieChief Human Resources Officer
|
Tax withholdingCommon Stock | 5,378 | $124.12 | $667,517.36 |
DisclosureSEC source: 0001776977-26-000007 · wk-form4_1771368375.xml · nonDerivative · entry 8 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,170 F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold. F3 · balance_after: 32,306 of the reported shares are held by the Cooke Family Trust of 2004 U/A 12/28/2004, of which the Reporting Person has voting and investment power. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:46 UTC |
Cooke JulieChief Human Resources Officer
|
GrantCommon Stock | 9,968 | $0.00 | $0.00 |
DisclosureSEC source: 0001776977-26-000007 · wk-form4_1771368375.xml · nonDerivative · entry 7 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,548 F2 · shares: On May 19, 2023, the Reporting Person was granted PRSUs representing the right to receive shares of the Issuer's common stock based upon the achievement of specified performance metrics over the three-year performance period ending on December 31, 2025. Effective February 13, 2026, the achievement of the applicable performance metrics and the resulting payout level were certified, and, as a result of such certification, the PRSUs vested at 125% of the target number of shares subject to the award. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:46 UTC |
Cooke JulieChief Human Resources Officer
|
Tax withholdingCommon Stock | 815 | $124.12 | $101,157.80 |
DisclosureSEC source: 0001776977-26-000007 · wk-form4_1771368375.xml · nonDerivative · entry 6 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,580 F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:46 UTC |
Cooke JulieChief Human Resources Officer
|
Exercise / conversionCommon Stock | 1,510 | $0.00 | $0.00 |
DisclosureSEC source: 0001776977-26-000007 · wk-form4_1771368375.xml · nonDerivative · entry 5 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,395 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:46 UTC |
Cooke JulieChief Human Resources Officer
|
Tax withholdingCommon Stock | 756 | $124.12 | $93,834.72 |
DisclosureSEC source: 0001776977-26-000007 · wk-form4_1771368375.xml · nonDerivative · entry 4 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,885 F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:46 UTC |
Cooke JulieChief Human Resources Officer
|
Exercise / conversionCommon Stock | 1,401 | $0.00 | $0.00 |
DisclosureSEC source: 0001776977-26-000007 · wk-form4_1771368375.xml · nonDerivative · entry 3 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,641 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:46 UTC |
BENEVICH ERICChief Commercial Officer
|
GrantRestricted Stock Unit · Derivative | 6,365 | $0.00 | $0.00 |
DisclosureSEC source: 0001643653-26-000011 · wk-form4_1771368412.xml · derivative · entry 13 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,365 Underlying: Common Stock · 6,365 shares Expires not disclosed F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F8 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030. F8 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:46 UTC |
BENEVICH ERICChief Commercial Officer
|
GrantStock Option · Derivative | 36,287 | $0.00 Strike: $124.12 | $0.00 |
DisclosureSEC source: 0001643653-26-000011 · wk-form4_1771368412.xml · derivative · entry 12 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,287 Underlying: Common Stock · 36,287 shares Expires 2036-02-13 F7 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2026 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:46 UTC |
BENEVICH ERICChief Commercial Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,083 | $0.00 | $0.00 |
DisclosureSEC source: 0001643653-26-000011 · wk-form4_1771368412.xml · derivative · entry 11 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,083 Underlying: Common Stock · 2,083 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 2,083 shares on February 13, 2024, vested as to 2,083 shares on February 13, 2025, vested as to 2,083 shares on February 13, 2026, and will vest as to 2,083 shares on February 13, 2027, subject to the terms and conditions of the award. F6 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 2,083 shares on February 13, 2024, vested as to 2,083 shares on February 13, 2025, vested as to 2,083 shares on February 13, 2026, and will vest as to 2,083 shares on February 13, 2027, subject to the terms and conditions of the award. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:46 UTC |
BENEVICH ERICChief Commercial Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,961 | $0.00 | $0.00 |
DisclosureSEC source: 0001643653-26-000011 · wk-form4_1771368412.xml · derivative · entry 10 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,924 Underlying: Common Stock · 1,961 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 1,961 shares on February 13, 2025, vested as to 1,961 shares on February 13, 2026, and will vest as to 1,962 shares on February 13, 2027, and 1,962 shares on February 13, 2028, subject to the terms and conditions of the award. F5 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 1,961 shares on February 13, 2025, vested as to 1,961 shares on February 13, 2026, and will vest as to 1,962 shares on February 13, 2027, and 1,962 shares on February 13, 2028, subject to the terms and conditions of the award. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:46 UTC |
BENEVICH ERICChief Commercial Officer
|
Tax withholdingCommon Stock | 8,963 | $124.12 | $1,112,487.56 |
DisclosureSEC source: 0001643653-26-000011 · wk-form4_1771368412.xml · nonDerivative · entry 8 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,190 F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:46 UTC |
BENEVICH ERICChief Commercial Officer
|
GrantCommon Stock | 16,613 | $0.00 | $0.00 |
DisclosureSEC source: 0001643653-26-000011 · wk-form4_1771368412.xml · nonDerivative · entry 7 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,153 F2 · shares: On May 19, 2023, the Reporting Person was granted PRSUs representing the right to receive shares of the Issuer's common stock based upon the achievement of specified performance metrics over the three-year performance period ending on December 31, 2025. Effective February 13, 2026, the achievement of the applicable performance metrics and the resulting payout level were certified, and, as a result of such certification, the PRSUs vested at 125% of the target number of shares subject to the award. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:46 UTC |
BENEVICH ERICChief Commercial Officer
|
Tax withholdingCommon Stock | 1,124 | $124.12 | $139,510.88 |
DisclosureSEC source: 0001643653-26-000011 · wk-form4_1771368412.xml · nonDerivative · entry 6 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,540 F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:46 UTC |
BENEVICH ERICChief Commercial Officer
|
Exercise / conversionCommon Stock | 2,083 | $0.00 | $0.00 |
DisclosureSEC source: 0001643653-26-000011 · wk-form4_1771368412.xml · nonDerivative · entry 5 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,664 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:46 UTC |
BENEVICH ERICChief Commercial Officer
|
Tax withholdingCommon Stock | 1,058 | $124.12 | $131,318.96 |
DisclosureSEC source: 0001643653-26-000011 · wk-form4_1771368412.xml · nonDerivative · entry 4 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,581 F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:46 UTC |
BENEVICH ERICChief Commercial Officer
|
Exercise / conversionCommon Stock | 1,961 | $0.00 | $0.00 |
DisclosureSEC source: 0001643653-26-000011 · wk-form4_1771368412.xml · nonDerivative · entry 3 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,639 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:45 UTC |
Lippoldt DarinChief Legal Officer
|
GrantRestricted Stock Unit · Derivative | 6,124 | $0.00 | $0.00 |
DisclosureSEC source: 0001504783-26-000011 · wk-form4_1771368335.xml · derivative · entry 14 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,124 Underlying: Common Stock · 6,124 shares Expires not disclosed F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F9 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030. F9 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:45 UTC |
Lippoldt DarinChief Legal Officer
|
GrantStock Option · Derivative | 34,909 | $0.00 Strike: $124.12 | $0.00 |
DisclosureSEC source: 0001504783-26-000011 · wk-form4_1771368335.xml · derivative · entry 13 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,909 Underlying: Common Stock · 34,909 shares Expires 2036-02-13 F8 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2026 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:45 UTC |
Lippoldt DarinChief Legal Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,083 | $0.00 | $0.00 |
DisclosureSEC source: 0001504783-26-000011 · wk-form4_1771368335.xml · derivative · entry 12 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,083 Underlying: Common Stock · 2,083 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F7 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 2,083 shares on February 13, 2024, vested as to 2,083 shares on February 13, 2025, vested as to 2,083 shares on February 13, 2026, and will vest as to 2,083 shares on February 13, 2027, subject to the terms and conditions of the award. F7 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 2,083 shares on February 13, 2024, vested as to 2,083 shares on February 13, 2025, vested as to 2,083 shares on February 13, 2026, and will vest as to 2,083 shares on February 13, 2027, subject to the terms and conditions of the award. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:45 UTC |
Lippoldt DarinChief Legal Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,017 | $0.00 | $0.00 |
DisclosureSEC source: 0001504783-26-000011 · wk-form4_1771368335.xml · derivative · entry 11 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,036 Underlying: Common Stock · 2,017 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 2,017 shares on February 13, 2025, vested as to 2,017 shares on February 13, 2026, and will vest as to 2,018 shares on February 13, 2027, and 2,018 shares on February 13, 2028, subject to the terms and conditions of the award. F6 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 2,017 shares on February 13, 2025, vested as to 2,017 shares on February 13, 2026, and will vest as to 2,018 shares on February 13, 2027, and 2,018 shares on February 13, 2028, subject to the terms and conditions of the award. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:45 UTC |
Lippoldt DarinChief Legal Officer
|
GiftCommon Stock | 365 | $0.00 | $0.00 |
DisclosureSEC source: 0001504783-26-000011 · wk-form4_1771368335.xml · nonDerivative · entry 9 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,729 F3 · shares: Represents gift/charitable contributions effective February 13, 2026. This is not a market transaction; thus no price has been reported. No value was received for the gifted shares. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:45 UTC |
Lippoldt DarinChief Legal Officer
|
Tax withholdingCommon Stock | 5,378 | $124.12 | $667,517.36 |
DisclosureSEC source: 0001504783-26-000011 · wk-form4_1771368335.xml · nonDerivative · entry 8 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,094 F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:45 UTC |
Lippoldt DarinChief Legal Officer
|
GrantCommon Stock | 9,968 | $0.00 | $0.00 |
DisclosureSEC source: 0001504783-26-000011 · wk-form4_1771368335.xml · nonDerivative · entry 7 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,472 F2 · shares: On May 19, 2023, the Reporting Person was granted PRSUs representing the right to receive shares of the Issuer's common stock based upon the achievement of specified performance metrics over the three-year performance period ending on December 31, 2025. Effective February 13, 2026, the achievement of the applicable performance metrics and the resulting payout level were certified, and, as a result of such certification, the PRSUs vested at 125% of the target number of shares subject to the award. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:45 UTC |
Lippoldt DarinChief Legal Officer
|
Tax withholdingCommon Stock | 1,124 | $124.12 | $139,510.88 |
DisclosureSEC source: 0001504783-26-000011 · wk-form4_1771368335.xml · nonDerivative · entry 6 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,504 F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:45 UTC |
Lippoldt DarinChief Legal Officer
|
Exercise / conversionCommon Stock | 2,083 | $0.00 | $0.00 |
DisclosureSEC source: 0001504783-26-000011 · wk-form4_1771368335.xml · nonDerivative · entry 5 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,628 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:45 UTC |
Lippoldt DarinChief Legal Officer
|
Tax withholdingCommon Stock | 1,089 | $124.12 | $135,166.68 |
DisclosureSEC source: 0001504783-26-000011 · wk-form4_1771368335.xml · nonDerivative · entry 4 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,545 F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:45 UTC |
Lippoldt DarinChief Legal Officer
|
Exercise / conversionCommon Stock | 2,017 | $0.00 | $0.00 |
DisclosureSEC source: 0001504783-26-000011 · wk-form4_1771368335.xml · nonDerivative · entry 3 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,634 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:45 UTC |
Delaet IngridChief Regulatory Officer
|
GrantRestricted Stock Unit · Derivative | 5,479 | $0.00 | $0.00 |
DisclosureSEC source: 0001965808-26-000005 · wk-form4_1771368298.xml · derivative · entry 13 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,479 Underlying: Common Stock · 5,479 shares Expires not disclosed F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F8 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030. F8 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:45 UTC |
Delaet IngridChief Regulatory Officer
|
GrantStock Option · Derivative | 31,234 | $0.00 Strike: $124.12 | $0.00 |
DisclosureSEC source: 0001965808-26-000005 · wk-form4_1771368298.xml · derivative · entry 12 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,234 Underlying: Common Stock · 31,234 shares Expires 2036-02-13 F7 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2026 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:45 UTC |
Delaet IngridChief Regulatory Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,359 | $0.00 | $0.00 |
DisclosureSEC source: 0001965808-26-000005 · wk-form4_1771368298.xml · derivative · entry 11 Delaet Ingrid · CIK 0001965808 · Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,359 Underlying: Common Stock · 1,359 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 1,358 shares on February 13, 2024, vested as to 1,358 shares on February 13, 2025, vested as to 1,359 shares on February 13, 2026, and will vest as to 1,359 shares on February 13, 2027, subject to the terms and conditions of the award. F6 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 1,358 shares on February 13, 2024, vested as to 1,358 shares on February 13, 2025, vested as to 1,359 shares on February 13, 2026, and will vest as to 1,359 shares on February 13, 2027, subject to the terms and conditions of the award. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.